Karyopharm announces updated Xpovio data in multiple myeloma
Karyopharm Therapeutics announced that two presentations highlighting new and updated data relating to Xpovio will be given at the American Society of Hematology Annual Meeting. The first study describes updated data from the Phase 1b/2 Stomp study evaluating the all oral regimen of selinexor in combination with Pomalyst and low-dose dexamethasone in patients with relapsed or refractory multiple myeloma. The second abstract describes new data on the use of selinexor and dexamethasone, either alone or in combination with standard approved therapies, in patients with multiple myeloma whose disease has progressed following experimental chimeric antigen receptor T-cell therapy. "We continue to be pleased with the efficacy and safety observed in the all oral selinexor plus Pomalyst arm of the Phase 1b/2 STOMP study, where patients with Pomalyst-naive and Revlimid (lenalidomide)-relapsed or -refractory myeloma achieved a 56% overall response rate and a 12-month progression free survival," said Sharon Shacham, PhD, MBA, Founder, President and Chief Scientific Officer of Karyopharm. "Another key study this year is the presentation of new data from patients treated with selinexor-based regimens after their myeloma had progressed following experimental CAR-T therapy. Although these data are early, six of seven patients whose disease relapsed after CAR-T achieved a response when treated with selinexor and dexamethasone alone or in combination with either Velcade or Kyprolis. There is currently very limited data regarding treatment options for patients whose disease has progressed following experimental CAR-T therapy, and we believe these encouraging results further reinforce the therapeutic activity of selinexor in patients with relapsed or refractory disease."